Shukra Pharmaceuticals signs term sheet for AI surgical robotics JV
Shukra Pharmaceuticals has executed a term sheet with Borns Medical Robotics to form a 60:40 joint venture for AI surgical robots. The new entity, B&S Robotics Private Limited, will leverage Shukra's distribution network and Borns' technology. Definitive agreements are expected within 120 days, with a potential future listing on Indian exchanges as a strategic goal.
*this image is generated using AI for illustrative purposes only.
Shukra Pharmaceuticals has executed a term sheet with Borns Medical Robotics Pte Ltd for a strategic joint venture focused on the design, manufacture, distribution and servicing of AI-enabled surgical robotic systems. The agreement marks a formal step towards establishing B&S Robotics Private Limited, with Shukra holding a 60% stake and Borns holding 40%.
Joint venture structure
The key parameters of the proposed joint venture are outlined below:
| Parameter: | Details |
|---|---|
| Joint venture entity: | B&S Robotics Private Limited |
| Shukra Pharmaceuticals stake: | 60% |
| Borns Medical Robotics stake: | 40% |
| Focus area: | AI surgical robots |
| Target markets: | India and APAC |
| Governance: | Five directors (three from Shukra, two from Borns) |
The formation of B&S Robotics Private Limited represents Shukra's entry into the medical robotics space. Shukra will contribute capital, its sales and distribution network, skilled team, market-development capabilities, branding support, infrastructure initiatives and financing ecosystem. Borns will contribute its technology platform, surgical robotic systems, relevant technology/IP support, manufacturing know-how and related technical capabilities.
Timeline and conditions
The term sheet was executed on August 13, 2026. The parties intend to enter into definitive agreements, including a Shareholders' Agreement, Articles of Association, Master IP Licensing Agreement and other ancillary documents. These long-form agreements are targeted within approximately 120 days from the execution of the term sheet, subject to satisfaction of applicable conditions precedent.
Conditions precedent include the establishment of the Borns Singapore entity, completion of mutual due diligence, independent valuation, applicable regulatory/FEMA/FDI confirmations, necessary corporate approvals, IP due diligence and regulatory pathway confirmation. The transaction is not currently classified as a related party transaction.
Strategic outlook
The joint venture aims to address the growing demand for advanced surgical technology across India and the APAC region. The term sheet contemplates that, subject to achievement of agreed milestones and applicable regulatory approvals, the parties may pursue a future demerger and listing of the joint venture entity on BSE and NSE. This potential listing is stated as a strategic objective rather than a guaranteed commitment.
The initial paid-up capital of B&S India is yet to be determined under the definitive agreements. Subscription is proposed in the ratio of 60:40. The term sheet itself does not specify any fixed immediate financial commitment or final investment amount by Shukra Pharmaceuticals.
Historical Stock Returns for Shukra Pharmaceuticals
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
What specific regulatory hurdles from FEMA or Indian medical device authorities could delay the 120-day timeline for finalizing the definitive agreements?
How might Shukra Pharmaceuticals' existing pharmaceutical distribution network be adapted to effectively service and maintain complex AI-enabled surgical robots?
Given the competitive landscape in APAC, what unique technological advantages does Borns Medical Robotics bring that differentiate B&S Robotics from established players like Medtronic or Intuitive Surgical?
15
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
